Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2016The Cancer Journal

Managing Adverse Events With Immune Checkpoint Agents

View Full Paper
Ask AI
Bookmark
Share

Authors

RDRamona DaduThe University of Texas MD Anderson Cancer CenterCZChrystia M. ZobniwThe University of Texas MD Anderson Cancer CenterADAdi DiabCleveland Clinic

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dadu et al. (2016) studied this question.

synapsesocial.com/papers/6a71ee40ac440176ef2a6cafhttps://doi.org/10.1097/ppo.0000000000000186
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pembrolizumab versus Ipilimumab in Advanced Melanoma2015 · 5,999 citations
  2. 2Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center2015 · 1,084 citations
  3. 3Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis2015 · 714 citations
  4. 4Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010 · 15,367 citations
  5. 5Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma2015 · 2,804 citations